Brief: Impel Neuropharma Provides Updates On Trudhesatm Launch And Recent Business Highlights
Jan 18 (Reuters) - Impel Neuropharma Inc IMPL.O :
* IMPEL NEUROPHARMA PROVIDES UPDATES ON TRUDHESATM LAUNCH
AND
RECENT BUSINESS HIGHLIGHTS
* IMPEL NEUROPHARMA INC - PLANNED INITIATION OF INP105
PROOF-OF-CONCEPT STUDY FOR AUTISM SPECTRUM DISORDER IN Q1 2022;
RESULTS ANTICIPATED Q4 2022
Source text: [ID: https://bit.ly/3532qZZ]
Further company coverage: IMPL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IPI Legacy Liquidation Co
See all newsBrief: Impel Pharmaceuticals- On Dec 19, 2023, Co And Impel NeuroPharma Australia Commenced Voluntary Chapter 11 Proceedings
Brief: Impel Pharmaceuticals Says On Dec 1 Michael Kalb Gave Notice Of Resignation From Position As CFO With Last Day To Be December 31
U.S. STOCKS ON THE MOVE-iRobot Corp, Faraday Future, Fisker
U.S. STOCKS ON THE MOVE-iRobot Corp, Fisker Inc, International Seaways Inc
Brief: Impel Pharmaceuticals Receives Delisting Notice From Nasdaq